Novo Nordisk A/S (NVO) News
Follow Novo Nordisk A/S (NVO) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 70 public stories across 39 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Novo Nordisk Reports Q3 Sales Growth, Raises 2026 Guidance
Sales rose 6% to 79.19 billion Danish kroner. Novo Nordisk raised its full-year sales and adjusted operating profit growth outlook to -2% to 2% at constant exchange rates, an improvement of approximately three percentage
EQUITY | Nov 04, 2026, 10:04 AM UTC
M
Novo Nordisk lifts outlook on obesity drug sales
Novo Nordisk raised its outlook for obesity drug sales.
EARNINGS | Nov 04, 2026, 09:30 AM UTC
M
Novo Nordisk Q3 Earnings Snapshot
EQUITY | Nov 04, 2026, 07:07 AM UTC
L
Novo Nordisk Reportedly Loses US Ruling to Block Eli Lilly Drug Ads
Novo Nordisk failed to convince a U.S. judge to block Eli Lilly weight-loss drug ads.
REGULATION | Oct 27, 2026, 08:53 AM UTC
H
Anthropic Claude’s Claimed Breakthrough in Biology Faces a Major Question — Scientist Says He Had Already Studied the Enzymes for 4 Years
Anthropic ’s claim that Claude autonomously discovered a novel enzyme system is reportedly facing scrutiny after a computational biologist questioned the source of the discovery. Mario Rodríguez Mestre said he and his co
LIVE | Sep 28, 2026, 01:55 PM UTC
L
Novo Pays Up to $1.3 Billion for Nanexa's Drug Delivery Tech
Novo Nordisk NYSE:NVO shares were unchanged in Copenhagen after the company signed a global exclusive license and collaboration deal worth up to 1.165 billion ($1.3 billion) with Nanexa, a Swedish drug delivery company.
EQUITY | Sep 25, 2026, 01:58 PM UTC
L
Huge News For Novo Nordisk Fans
Novo Nordisk NYSE:NVO is considering hair loss as one possible area for future expansion as it looks beyond its core obesity and diabetes franchises, with the idea emerging alongside a broader strategy reset.Chief Scient
NEWS | Sep 23, 2026, 03:11 PM UTC
M
Lilly rises after Novo reports CagriSema beats 5mg tirzepatide
Novo Nordisk said CagriSema beat tirzepatide’s 5-milligram dose in a late-stage diabetes study. Lilly shares still climbed about 1.2% to $1,166.74.
EQUITY | Sep 21, 2026, 07:11 PM UTC
H
Crude Oil Down 4%; Intel Shares Move Higher
U.S. stocks traded higher midway through trading, with the S&P 500 gaining over 1% on Monday. The Dow traded up 0.45% to 51,917.33 while the NASDAQ climbed 1.77% to 26,992.96. The S&P 500 also rose, gaining, 1.16% to 7,7
LIVE | Sep 21, 2026, 04:04 PM UTC
M
Novo Nordisk shares slide after 2030 strategic ambitions
Novo Nordisk (NVO) shares fell about 5.96% in Copenhagen trading after the company used its London Capital Markets Day to outline 2030 strategic ambitions under new CEO Mike Doustdar.
EQUITY | Sep 21, 2026, 12:21 PM UTC
L
NVO - NOVO: CHMP RECOMMENDS EU APPROVAL OF FREHEMGO® (DENECIMIG)
NVO - NOVO: CHMP RECOMMENDS EU APPROVAL OF FREHEMGO® (DENECIMIG)
NEWS | Sep 17, 2026, 02:16 PM UTC
M
Novo Nordisk adds Anthropic's Claude to drug-research workflow
Novo Nordisk (NYSE: NVO) will test Anthropic’s Claude Science on selected scientific questions and deploy it in its drug-research workflow, Reuters reported.
EQUITY | Sep 16, 2026, 09:11 PM UTC
L
Novo Nordisk Stock Falls After Major Rebrand
Novo Nordisk NYSE:NVO shares fell 2% on Tuesday even after the drugmaker introduced a new brand identity and updated its corporate culture, as an analyst said the changes may need to be supported by a broader strategy.BM
EQUITY | Sep 15, 2026, 03:51 PM UTC
H
Notable healthcare headlines for the week: UnitedHealth, Amgen, and CooperCompanies in focus
Wall Street rallied on Friday after the latest consumer inflation report came in broadly in line with expectations, helping ease concerns over price pressures and supporting a rebound across risk assets.On Friday, the Do
NEWS | Sep 13, 2026, 01:11 PM UTC
H
Notable analyst calls this week: Lockheed Martin, Meta and Intel among top picks
The S&P 500 (SP500) closed in the green on Friday, after the week saw the latest consumer inflation report coming in largely in line with expectations, as well as earnings reports from companies including Oracle and Adob
EARNINGS | Sep 12, 2026, 02:11 PM UTC
L
JPMorgan Tweaks Hims & Hers Stock Outlook on Key Risk
Hims & Hers Health NYSE:HIMS faces a more complicated growth path as regulatory pressure reshapes its weight-loss business, prompting JPMorgan to resume coverage at Neutral with a $32 price target. The target implies rou
EQUITY | Sep 11, 2026, 09:14 PM UTC
L
Novo Nordisk shares trade flat at $44.535 on Wegovy China approval
Novo Nordisk shares were quoted at $44.535 and stayed flat on Thursday morning. China cleared Wegovy for metabolic dysfunction-associated steatohepatitis (MASH), described as the first approved GLP-1 receptor agonist in
EQUITY | Sep 10, 2026, 06:21 PM UTC
M
Novo Nordisk shares fall nearly 2% after two trial cancellations
Novo Nordisk stock traded at $46.60 Monday, down nearly 2%, after Reuters reported it stopped two ziltivekimab heart-failure trials.
EQUITY | Sep 07, 2026, 05:56 PM UTC
M
Novo Nordisk drops about 2% as Wegovy launches in Germany
Novo Nordisk fell about 2% to $46.625 on Friday as Wegovy’s once-daily oral pill rollout reached its first EU market, with Germany joining markets that already sell the treatment.
EQUITY | Sep 04, 2026, 05:16 PM UTC
M
FDA warns of severe risks from misbranded GLP-1 weight-loss drugs
The FDA warned patients and providers about severe health risks from unapproved and compounded GLP-1 weight-loss drugs, including illegally marketed semaglutide and tirzepatide. Hims & Hers stock closed 3.85% lower Tuesd
REGULATION | Sep 02, 2026, 11:40 AM UTC
M
Novo Nordisk rises as Wegovy pill rolls out in Germany
Novo Nordisk rose about 0.5% to $45.545 after rolling out its Wegovy pill in Germany, bringing the oral weight-loss treatment to the EU’s largest pharmaceutical market.
EQUITY | Sep 01, 2026, 05:36 PM UTC
L
Novo's Wegovy Pill Enters China Behind Lilly
Novo's Wegovy Pill Enters China Behind Lilly
GEOPOLITICS | Aug 28, 2026, 05:56 PM UTC
L
Novo sends oral Wegovy into China’s GLP-1 race
Novo has sent oral Wegovy into China’s GLP-1 market race behind Lilly.
GEOPOLITICS | Aug 27, 2026, 07:36 PM UTC
H
Boston Scientific details global disruption after cybersecurity incident
Boston Scientific identified a cybersecurity incident that caused global operational disruptions, including delays in processing and shipping customer orders. The company says system access remains limited and the restor
EARNINGS | Aug 26, 2026, 06:17 PM UTC
L
Lexicon earns third $10M milestone from Novo Nordisk
Lexicon Pharmaceuticals says it earned a third $10 million milestone payment from Novo Nordisk after a key phase 1 development milestone for LX9851.
MNA | Aug 24, 2026, 12:31 PM UTC
M
Novo begins study to find lowest effective dose for Wegovy pill
Novo Nordisk (NVO) begins a study to identify the lowest effective dose for a Wegovy pill formulation, according to Reuters coverage cited by Hammerstone MarketTalk.
EQUITY | Aug 19, 2026, 01:40 PM UTC
M
ATAI, CRDF, GAP, LEGN, NVO Downgraded
ATAI, CRDF, GAP, LEGN, and NVO downgraded by various analysts
EQUITY | Aug 12, 2026, 10:47 AM UTC
M
NVO Downgraded to Hold at Berenberg
NVO downgraded to Hold at Berenberg with price target 47 from 50
EQUITY | Aug 12, 2026, 09:14 AM UTC
M
Novo Nordisk Selects Amazon AWS
Novo Nordisk chooses Amazon AWS as cloud partner
EQUITY | Aug 10, 2026, 12:16 PM UTC
M
Denmark's Novo Nordisk Wins Court Injunction
Novo Nordisk wins court case protecting patients
REGULATION | Aug 05, 2026, 01:44 PM UTC
M
Novo Nordisk Ahead Of Plan On 8 Billion DKK Savings
Novo Nordisk exceeds savings target
EQUITY | Aug 05, 2026, 11:26 AM UTC
M
Novo Nordisk Launches Wegovy In Germany
Novo Nordisk launches Wegovy in Germany
EQUITY | Aug 05, 2026, 11:16 AM UTC
M
Novo Nordisk to Accelerate Early-Stage Asset Development
Novo Nordisk accelerates early-stage asset development
EQUITY | Aug 05, 2026, 10:04 AM UTC
M
Novo Nordisk CEO Rules Out Major Deals
Novo Nordisk has no plans for major deals
EQUITY | Aug 05, 2026, 10:03 AM UTC
M
Novo Nordisk Sees Wegovy Profitability Improving
Novo Nordisk expects Wegovy pill profitability to improve
EQUITY | Aug 05, 2026, 08:34 AM UTC
M
Novo Nordisk CEO Rules Out More Major Cost Cuts
Novo Nordisk has no plans for more major cost cuts
EQUITY | Aug 05, 2026, 06:29 AM UTC
L
Ozempic Maker Novo Nordisk Raises Outlook but Sales Fall on Tough Comparison, Stock Tanks
Novo Nordisk A/S (NYSE: NVO ) stock is trading lower on Tuesday despite the company raising its fiscal 2026 guidance. The weight loss drug maker reported second quarter sales of 78.488 billion Danish kroner, up 2% year o
EARNINGS | Aug 04, 2026, 06:38 PM UTC
L
Novo Nordisk Raises Outlook On GLP-1 Sales
Novo Nordisk increases outlook due to higher GLP-1 sales
EARNINGS | Aug 04, 2026, 04:50 PM UTC
L
NVO FDA approves pluvicto for psma+ metastatic hormone-sensitive prostate cancer (mhspc), advancing potential new standard of Care across me
NVO FDA approves pluvicto for psma+ metastatic hormone-sensitive prostate cancer (mhspc), advancing potential new standard of Care across metastatic disease
REGULATION | Jul 31, 2026, 08:27 PM UTC
H
Novo Nordisk Says Anti-Inflammatory Drug Trial Fails to Cut Cardiovascular Risk in High Risk Patients
Novo Nordisk A/S (NYSE: NVO ) stock plunged on Friday after the company announced disappointing headline results from its ZEUS Phase 3 cardiovascular outcomes trial. The data revealed that its experimental drug ziltiveki
CENTRAL_BANK | Jul 31, 2026, 12:20 PM UTC
H
NVO: Ziltivekimab Fails to Show MACE Risk Reduction
NVO's ziltivekimab misses MACE risk reduction target
EQUITY | Jul 31, 2026, 11:27 AM UTC
L
Novo Volatility Drops
Novo volatility decreases
EQUITY | Jul 31, 2026, 11:23 AM UTC
L
Novo Nordisk: Zeus Outcome Won't Impact 2026 Profit Outlook
Novo Nordisk's Zeus outcome has no impact on 2026 profit outlook
EARNINGS | Jul 31, 2026, 11:23 AM UTC
L
Novo Nordisk: Zeus Trial Shows Similar Adverse Event Rates
Novo Nordisk reports similar adverse event rates in Zeus trial
EARNINGS | Jul 31, 2026, 11:21 AM UTC
L
NVO high risk, high reward into Ph3 ZEUS CV readout @ BMO
NVO high risk, high reward into Ph3 ZEUS CV readout @ BMO
EQUITY | Jul 28, 2026, 11:41 AM UTC
L
NVO (corrects symbol) said it is seeking a preliminary U.S. court injunction to immediately block obesity and Diabetes drug advertisements
NVO (corrects symbol) said it is seeking a preliminary U.S. court injunction to immediately block obesity and Diabetes drug advertisements by LLY
EQUITY | Jul 24, 2026, 11:05 AM UTC
L
Novo Nordisk pursues preliminary injunction to block Eli Lilly weight-loss drug ads
Denmark's Novo Nordisk said on Tuesday that it had sued Lilly, arguing consumers were being misled about how the companies' products compare.
EQUITY | Jul 24, 2026, 10:20 AM UTC
L
NVO crux collaborates with Novo nordisk to offer access to wegovy and other obesity management medications Crux: Co and Novo nordisk to expa
NVO crux collaborates with Novo nordisk to offer access to wegovy and other obesity management medications Crux: Co and Novo nordisk to expand affordable and simplified access to authentic anti-obesity medications for em
EQUITY | Jul 23, 2026, 01:03 PM UTC
H
What You Missed On Wall Street On Tuesday
The major averages finished broadly higher as technology shares led gains ahead of a stretch of earnings from some of the market's largest companies. The focus this week is on corporate earnings, with Alphabet, Tesla, IB
EARNINGS | Jul 21, 2026, 08:26 PM UTC
L
LLY NVO Eli Lilly: rather than compete on the merits of its products, Novo is asking court to stop lilly from communicating results of that
LLY NVO Eli Lilly: rather than compete on the merits of its products, Novo is asking court to stop lilly from communicating results of that trial
EQUITY | Jul 21, 2026, 02:43 PM UTC
L
LLY NVO Eli Lilly on Novo nordisk lawsuit- "we stand firmly behind our advertising" Eli Lilly: we will continue to focus on the Science and
LLY NVO Eli Lilly on Novo nordisk lawsuit- "we stand firmly behind our advertising" Eli Lilly: we will continue to focus on the Science and defend against Novo nordisk lawsuit vigorously
REGULATION | Jul 21, 2026, 02:43 PM UTC
L
NVO LLY (more, Statnews) Novo Nordisk on Tuesday sued Eli Lilly for allegedly running a “deceptive” Ad campaign that uses “outdated clinical
NVO LLY (more, Statnews) Novo Nordisk on Tuesday sued Eli Lilly for allegedly running a “deceptive” Ad campaign that uses “outdated clinical trials” to make its obesity and Diabetes drugs appear more effective, marking a
REGULATION | Jul 21, 2026, 11:43 AM UTC
L
NVO LLY Novo nordisk sues Eli Lilly in U.S. federal court, alleging claim under the lanham act, court records show
NVO LLY Novo nordisk sues Eli Lilly in U.S. federal court, alleging claim under the lanham act, court records show
EQUITY | Jul 21, 2026, 11:33 AM UTC
H
Sector Update: Healthcare Stocks Advance Late Afternoon
() -- Healthcare stocks rose late Wednesday afternoon, with the NYSE Healthcare Index adding 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.1%. The iShares Biotechnology ETF (IBB) added 0
EARNINGS | Jul 15, 2026, 07:47 PM UTC
H
Sector Update: Healthcare Stocks Advance in Afternoon Trading
() -- Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 0.4% and the State Street Health Care Select Sector SPDR ETF (XLV) increasing 0.3%. The iShares Biotechnology ETF (IBB) added 0.3%.
EARNINGS | Jul 15, 2026, 05:41 PM UTC
L
NVO says committed to launching Wegovy pill in more countries in second half of 2026
NVO says committed to launching Wegovy pill in more countries in second half of 2026
EQUITY | Jul 15, 2026, 03:52 PM UTC
L
NVO shares near highs up nearly 3% after WSJ noted overnight the launch of weight-loss pills is the hottest battle in Pharma. So far, LLY El
NVO shares near highs up nearly 3% after WSJ noted overnight the launch of weight-loss pills is the hottest battle in Pharma. So far, LLY Eli Lilly is losing to rival Novo Nordisk Link To Story from WSJ.com
EQUITY | Jul 15, 2026, 02:30 PM UTC
L
CVS UNH NVO CVS Health's (CVS) Caremark has finalized a settlement with the U.S. Federal Trade Commission in which it agreed to curb use of
CVS UNH NVO CVS Health's (CVS) Caremark has finalized a settlement with the U.S. Federal Trade Commission in which it agreed to curb use of after-market discounts known as rebates and count consumers' TrumpRx purchases t
GEOPOLITICS | Jul 14, 2026, 06:22 PM UTC
L
AdaptHealth Flags Material Breach After Threat Actor Accessed Patient Management Systems
AdaptHealth Corp. (NASDAQ: AHCO ) on Thursday disclosed that it is investigating a cybersecurity incident after a threat actor gained unauthorized access to certain company systems and exfiltrated data. The company class
REGULATION | Jul 06, 2026, 02:34 PM UTC
L
Novo Nordisk price target raised to DKK 300 from DKK 280 at HSBC
HSBC raised the firm's price target on Novo Nordisk to DKK 300 from DKK 280 and keeps a Hold rating on the shares. In a sector note on Healthcare, HSBC adjusted target prices on the prospects of the sector's relative out
EQUITY | Jul 06, 2026, 02:24 PM UTC